Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01371851 · ClinicalTrials.gov registry record · Phase 1
Doxazosin for Psychostimulant Dependence
A Phase 1 study of Methamphetamine or Cocaine Dependence, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT01371851 is a Phase 1 study of Methamphetamine or Cocaine Dependence that has completed, run by University of Arkansas. The registered enrollment target is 22 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01371851, a Phase 1 study of Methamphetamine or Cocaine Dependence, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
Psychostimulant dependence is a major public health problem and no medications have been shown to be very effective in treating this disorder. Thus, the investigators wish to study whether a blood pressure drug thought to reduce drug craving through its interaction at particular adrenergic receptors - doxazosin - can dredge cocaine use relative to placebo in psychostimulant dependent participants enrolled in an 8-week, randomized, double blind, placebo-controlled outpatient clinical trial. Our hypothesis is that doxazosin will reduce cocaine use relative to placebo in psychostimulant dependent participants.
Conditions Studied
Interventions
- DRUG Doxazosin extended release
Study Locations (1)
Arkansas
- UAMS Psychiatric Research Institute - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2011-06 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01371851
The ClinicalTrials.gov registry entry for NCT01371851 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Methamphetamine or Cocaine Dependence appearing as the primary indexed condition, and to 1 intervention - of which Doxazosin extended release is the first listed.
NCT01371851 reports 1 study location spanning 1 distinct geographic area - top geographies include Arkansas.
Frequently Asked Questions
What is clinical trial NCT01371851 about?
NCT01371851 is a clinical study titled "Doxazosin for Psychostimulant Dependence". Psychostimulant dependence is a major public health problem and no medications have been shown to be very effective in treating this disorder. Thus, the investigators wish to study whether a blood pressure drug thought to reduce drug craving through its interaction at particular adrenergic receptors...
What is the current status of trial NCT01371851?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2011-06. Estimated completion is 2014-05.
What conditions does trial NCT01371851 study?
This clinical trial studies the following conditions: Methamphetamine or Cocaine Dependence.
What interventions are being tested in trial NCT01371851?
The interventions under investigation include: Doxazosin extended release (DRUG).
Who is sponsoring clinical trial NCT01371851?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01371851 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.